Cases & Deals

  • Home
  • Practices
  • Novexel acquired by AstraZeneca for $505 million

Share

Novexel acquired by AstraZeneca for $505 million

March 2010

Client(s) Novexel SA

Jones Day represented Novexel SA in its $505 million acquisition by AstraZeneca PLC. The deal centered on Novexel's two most advanced drug programs, CAZ104 and CEF104, which are in development to treat bugs that have gained resistance to existing antibiotics, a trend that is spurring research into new anti-infective medicines.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.